OKYO PHARMA LTD SP.ADR/65 Market Cap ($38.38 Million)
Market Cap & Net Worth: OKYO PHARMA LTD SP.ADR/65 (OK10)
OKYO PHARMA LTD SP.ADR/65 market cap. OKYO PHARMA LTD SP.ADR/65 (F:OK10) has a market capitalization of $38.38 Million (€32.83 Million) as of November 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #22666 globally and #1998 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OKYO PHARMA LTD SP.ADR/65's stock price €1.36 by its total outstanding shares 28219900 (28.22 Million). Also see OK10 cash generation efficiency for how efficiently the company converts equity into cash flow.
OKYO PHARMA LTD SP.ADR/65 Market Cap History (2022–2026)
OKYO PHARMA LTD SP.ADR/65 market cap history from 2022 to 2026. Data shows change from $65.65 Million to $44.87 Million (-9.08% CAGR). Check OK10 stock price for real-time trading data and today's change.
OKYO PHARMA LTD SP.ADR/65 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OKYO PHARMA LTD SP.ADR/65's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of OKYO PHARMA LTD SP.ADR/65 to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of OK10 by Market Capitalization
Companies near OKYO PHARMA LTD SP.ADR/65 in the global market cap rankings as of November 3, 2026. Also see OK10 total assets for a full breakdown of the balance sheet.
Key companies related to OKYO PHARMA LTD SP.ADR/65 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of OKYO PHARMA LTD SP.ADR/65 (2022–2026)
Market capitalization of OKYO PHARMA LTD SP.ADR/65 from 2022 to today. Between 2022 and today, OKYO PHARMA LTD SP.ADR/65's market cap moved from $65.65 Million to $ 44.87 Million, with a yearly change of -9.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €44.87 Million | 0.00% |
| 2025 | €44.87 Million | 0.00% |
| 2024 | €44.87 Million | 0.00% |
| 2023 | €44.87 Million | -31.66% |
| 2022 | €65.65 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of OKYO PHARMA LTD SP.ADR/65 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $38.38 Million USD |
| MoneyControl | $38.38 Million USD |
| MarketWatch | $38.38 Million USD |
| marketcap.company | $38.38 Million USD |
| Reuters | $38.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OKYO PHARMA LTD SP.ADR/65
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptid… Read more